Oxford, UK, October 20th, 2011 – PharmaVentures today announced the launch of PharmaDeals® Essential Deal Trends: Oncology 2011. This new series of reports is essential reading for everyone involved in developing and commercialising new drugs. The first report in the series focuses on oncology.
Oncology is the single most active deal making therapeutic area in the pharmaceutical and biotechnology industry. With such a high intensity of deal making, executives across the industry need the best information and insight to support their business decisions in this vital drive to make better drugs available for patients. PharmaDeals Essential Deal Trends: Oncology 2011 provides the data and insight that dealmakers need to be as effective as possible. Featuring all the key providers of therapies in the oncology field, including Pfizer, Genentech, Sanofi, Merck, GSK and others, the Essential Deal Trends series provides the most comprehensive deal trends coverage available. Other key deal intensive therapeutic areas including cardiovascular, CNS and respiratory will be published in the following months. Available in the iReport format with over 100 tables and figures in each report, you can extract data and tables for your own analysis and presentations.
Fintan Walton, Chief Executive of PharmaVentures, says, “Deal makers from large pharmaceutical companies to small biotechs tell us they need a high quality publication that helps them best understand the key players and deal trends in this and other vital areas of medicine. We are proud to be able to use our extensive data resources and analytical insight to produce this first in a series of key reports for the industry.”
For further information, contact:
Lisa Holloway
Senior Direct Marketing Manager
+44 1865 332700
lisa.holloway@pharmaventures.com
– ends –